Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest cancers in oncology
because of its increasing incidence and poor survival rate. More than 90% of PDAC patients …

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It
has a poor response to conventional therapy and has an extremely poor 5-year survival rate …

Pancreatic ductal adenocarcinoma (PDAC) is classified as a cancer with high metastasis so
that its mortality rate is high and most of the patients could not survive longer than 5 years …

Pancreatic cancer is a human malignancy with one of the highest mortality rates and little
progress has been achieved in its treatment in recent decades. Further improvement to the …

Simple Summary Pancreatic ductal adenocarcinoma is one of the deadliest malignancies in
humans. Despite advances in systemic therapy, prognosis still remains poor. However …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human cancers
worldwide. Little progress has been made in recent years concerning its diagnosis and …

Targeting the RAS pathway remains the holy grail of precision oncology. In the case of
pancreatic ductal adenocarcinomas (PDAC), 90–92% harbor mutations in the oncogene …

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers with a dismal
7% 5-year survival rate and is projected to become the second leading cause of cancer …

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease, whose main molecular trait
is the MAPK pathway activation due to KRAS mutation, which is present in 90% of cases …

The most frequent mutated oncogene family in the history of human cancer is the RAS gene
family, including NRAS, HRAS, and, most importantly, KRAS. A hallmark of pancreatic …